


We claim:

DEAV2003/0020

Dr. WI

1. A compound of formula I:



5

wherein

Ring A is (C₃-C₈)-cycloalkanediyl or (C₃-C₈)-cycloalkenediyl, wherein one or more carbon atoms in said (C₃-C₈)-cycloalkane- and (C₃-C₈)-cycloalkenediyl groups may be replaced by oxygen atoms;

10

R₁, R₂ are each independently H, (C₁-C₆)-alkyl, (C₃-C₈)-cycloalkyl or (C₆-C₁₀)-aryl;

R₃ is (C₃-C₆)-cycloalkyl or (C₁-C₁₂)-alkyl, each of which is optionally substituted by (C₆-C₁₀)-aryl, (C₅-C₆)-heteroaryl or (C₃-C₆)-cycloalkyl, and wherein said (C₆-C₁₀)-aryl, (C₅-C₆)-heteroaryl and (C₃-C₆)-cycloalkyl substituents are themselves optionally substituted by (C₁-C₆)-alkyl, (C₁-C₆)-alkoxy, Cl, Br, I, CO-(C₁-C₆)-alkyl, CO-O(C₁-C₆)-alkyl, CO-NH(C₁-C₆)-alkyl or CO-N((C₁-C₆)-alkyl)₂;

20

X is (C₁-C₆)-alkanediyl, wherein one or more carbon atoms therein are optionally replaced by oxygen atoms;

25 Y₁ is CO or a bond;

Y₂ is NH or (C₁-C₁₂)-alkanediyl wherein one or more carbon atoms therein are optionally replaced by oxygen atoms;

30 R₄ is (C₁-C₈)-alkyl;

R5 is H or (C₁-C₆)-alkyl;

R6 is H;

5

and pharmaceutically acceptable salts thereof.

2. The compound of Claim 1 wherein:

10 Ring A is (C₃-C₈)-cycloalkane-1,3-diyl;

R1, R2 are each independently H, (C₁-C₆)-alkyl, (C₃-C₈)-cycloalkyl or (C₆-C₁₀)-aryl;

15 R3 is (C₁-C₁₂)-cycloalkyl optionally substituted by phenyl, wherein said phenyl substituent is optionally substituted by (C₁-C₆)-alkyl;

X is (C₁-C₆)-alkanediyl wherein one carbon atom therein is optionally replaced by an oxygen atom;

20

Y₁ is CO or a bond;

Y₂ is NH or (C₁-C₆)-alkanediyl wherein one carbon atom therein is optionally replaced by an oxygen atom;

25

R4 is (C₁-C₈)-alkyl;

R5 is H or (C₁-C₆)-alkyl; and

30 R6 is H.

3. The compound of Claim 2 wherein:

Ring A is cyclohexane-1,3-diyl;

- R1, R2 are each independently H, (C₁-C₆)-alkyl, (C₃-C₈)-cycloalkyl or phenyl;
- 5 R3 is (C₁-C₁₂)-alkyl optionally substituted by phenyl, wherein said phenyl substituent is optionally substituted by methyl;
- X is (C₁-C₆)-alkanediyl wherein the carbon atom adjacent to ring A is optionally replaced by an oxygen atom;
- 10 Y₁ is CO or a bond;
- Y₂ is NH or (C₁-C₆)-alkanediyl wherein one carbon atom therein is optionally replaced by an oxygen atom;
- 15 R4 is (C₁-C₈)-alkyl;
- R5 is H or (C₁-C₄)-alkyl; and
- R6 is H.
- 20 4. The compound of Claim 3 wherein:
- Ring A is cyclohexane-1,3-diyl;
- 25 R1 is H;
- R2 is (C₁-C₆)-alkyl, (C₃-C₈)-cycloalkyl or phenyl;
- 30 R3 is (C₁-C₈)-alkyl optionally substituted by phenyl, wherein said phenyl substituent is optionally substituted by methyl;
- X is CH₂CH₂O;
- Y₁ is CO or a bond;

Y₂ is NH or (C₁-C₄)-alkanediyl;

R₄ is (C₁-C₆)-alkyl;

5

R₅ is H or (C₁-C₄)-alkyl; and

R₆ is H.

10

5. The compound of Claim 4, wherein the bond X-ring A-Y₁ is cis-configured.

6. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and one or more compounds of Claim 1.

15

7. The pharmaceutical composition of Claim 6 further comprising at least one additional active ingredient.

20

8. The pharmaceutical composition of Claim 7 wherein said additional active ingredient has favorable effects on metabolic disturbances or disorders.

9. The pharmaceutical composition of Claim 7 wherein said additional active ingredient is an antidiabetic.

25

10. The pharmaceutical composition of Claim 7 wherein said additional active ingredient is a lipid modulator.

30

11. A method of treating disorders of fatty acid metabolism and glucose utilization comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1.

12. A method of treating disorders of insulin resistance comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1.

13. A method of treating diabetes mellitus including the prevention of the sequelae associated therewith comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1.

5

14. A method of treating dyslipidemia and sequelae associated therewith comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1.

10 15. A method of treating metabolic syndrome and conditions associated therewith comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1.

15 16. A method of treating disorders of fatty acid metabolism and glucose utilization comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1 in combination with at least one further active compound.

20 17. A method of treating disorders of insulin resistance comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1 in combination with at least one further active compound.